Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Machupo
- Development stage
- Preclinical
- Lead developer
- LeafBio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Machupo is a preclinical-stage monoclonal antibody being developed by LeafBio (a subsidiary of Mapp Biopharmaceutical) for the treatment of Machupo virus infection (Bolivian hemorrhagic fever). Administered via intravenous (IV) infusion, the antibody is designed to target the Machupo virus, specifically neutralizing the viral glycoprotein to prevent viral entry and replication. The program is currently in the discovery or preclinical stage of development.
- Other names
- Machupo virus antibodyMachupo virus monoclonal antibody
02
Targets
Machupo virus glycoprotein complex
Beyond the preview
Go deeper on Machupo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Machupo.